Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies
Authors
Keywords
-
Journal
BMC Medicine
Volume 17, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-01
DOI
10.1186/s12916-019-1433-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective
- (2019) Ella Zomer et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events
- (2019) Thomas S. G. Sehested et al. JAMA Cardiology
- Tissue-specific epigenetics of atherosclerosis-related ANGPT and ANGPTL genes
- (2019) Kenneth C Ehrlich et al. Epigenomics
- T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword
- (2019) Karin H. Simons et al. Nature Reviews Cardiology
- Evidence-Based Cardiovascular Risk Management in Diabetes
- (2019) Arshag D. Mooradian American Journal of Cardiovascular Drugs
- OUP accepted manuscript
- (2018) EUROPEAN HEART JOURNAL
- Immune modulatory effects of statins
- (2018) Robert Zeiser IMMUNOLOGY
- Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases
- (2018) Aikaterini Arida et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Mechanism of Development of Atherosclerosis and Cardiovascular Disease in Diabetes Mellitus
- (2018) Naoto Katakami Journal of Atherosclerosis and Thrombosis
- Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
- (2018) Paul M Ridker et al. LANCET
- Statins Therapy for Connective Tissue Diseases: New Therapeutic Opportunities
- (2018) Przemyslaw J. Kotyla et al. Endocrine Metabolic & Immune Disorders-Drug Targets
- Inflammation: the new cardiovascular risk factor
- (2018) Thomas F Lüscher EUROPEAN HEART JOURNAL
- The role of B cells in atherosclerosis
- (2018) Andrew P. Sage et al. Nature Reviews Cardiology
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
- (2018) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases
- (2017) Renate M Hoogeveen et al. EUROPEAN HEART JOURNAL
- HIV-1–Associated Atherosclerosis
- (2017) Alison Kearns et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Interleukin-1 Beta as a Target for Atherosclerosis Therapy
- (2017) Peter Libby JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The NLRP3 inflammasome in acute myocardial infarction
- (2017) Stefano Toldo et al. Nature Reviews Cardiology
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epigenetics of Atherosclerosis: Emerging Mechanisms and Methods
- (2017) Nadiya Khyzha et al. TRENDS IN MOLECULAR MEDICINE
- Genetic and Epigenetic Determinants in Autoinflammatory Diseases
- (2017) Damiana Álvarez-Errico et al. Frontiers in Immunology
- Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms
- (2016) Amirhossein Sahebkar et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering
- (2016) Giuseppe Danilo Norata et al. CARDIOVASCULAR RESEARCH
- From C-Reactive Protein to Interleukin-6 to Interleukin-1
- (2016) Paul M Ridker CIRCULATION RESEARCH
- Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial
- (2016) Ola Kleveland et al. EUROPEAN HEART JOURNAL
- Circulating Levels of IL‐6 Receptor and gp130 and Long‐Term Clinical Outcomes in ST‐Elevation Myocardial Infarction
- (2016) Vibeke N. Ritschel et al. Journal of the American Heart Association
- START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus Infection
- (2016) Mark J. Siedner Open Forum Infectious Diseases
- PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse LiverSignificance
- (2015) Annie Demers et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-ITCLINICAL PERSPECTIVES
- (2015) Erin A. Bohula et al. CIRCULATION
- Flow-dependent epigenetic DNA methylation regulates endothelial gene expression and atherosclerosis
- (2014) Jessilyn Dunn et al. JOURNAL OF CLINICAL INVESTIGATION
- Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration
- (2014) Colette J Smith et al. LANCET
- The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia–reperfusion injury
- (2013) Øystein Sandanger et al. CARDIOVASCULAR RESEARCH
- Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis
- (2013) Roland Klingenberg et al. JOURNAL OF CLINICAL INVESTIGATION
- Upregulated NLRP3 Inflammasome Activation in Patients With Type 2 Diabetes
- (2012) Hye-Mi Lee et al. DIABETES
- Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
- (2012) Stefan M. Nidorf et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
- (2012) LANCET
- Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
- (2011) Nicola Ferri et al. ATHEROSCLEROSIS
- Comparative assessment of vascular function in autoimmune rheumatic diseases: Considerations of prevention and treatment
- (2011) Pál Soltész et al. AUTOIMMUNITY REVIEWS
- Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
- (2011) C. A. Dinarello BLOOD
- Inflammasome Activation of Cardiac Fibroblasts Is Essential for Myocardial Ischemia/Reperfusion Injury
- (2011) Masanori Kawaguchi et al. CIRCULATION
- Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes
- (2011) V. U. Ozkurede et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Relation of Baseline High-Sensitivity C-Reactive Protein Level to Cardiovascular Outcomes With Rosuvastatin in the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)
- (2010) Paul M. Ridker et al. AMERICAN JOURNAL OF CARDIOLOGY
- Effect of Ezetimibe on Hepatic Fat, Inflammatory Markers, and Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Subjects on a Weight Loss Diet
- (2010) D. C. Chan et al. DIABETES CARE
- NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
- (2010) Peter Duewell et al. NATURE
- Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect
- (2009) D Gómez-Garre et al. BRITISH JOURNAL OF PHARMACOLOGY
- Induction of the Cytoprotective Enzyme Heme Oxygenase-1 by Statins Is Enhanced in Vascular Endothelium Exposed to Laminar Shear Stress and Impaired by Disturbed Flow
- (2009) Faisal Ali et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
- (2009) Paul M Ridker et al. LANCET
- CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer
- (2009) Cameron R Stewart et al. NATURE IMMUNOLOGY
- A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism
- (2009) Robert J. Glynn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
- (2008) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Association of C-Reactive Protein and CRP Genotype with Coronary Heart Disease: Findings from Five Studies with 4,610 Cases amongst 18,637 Participants
- (2008) Debbie A. Lawlor et al. PLoS One
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started